Drug Trial Radar · NCT06126315
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
246
Planned (sponsor's estimate)
Start
Mar 26, 2025
Primary completion
Apr 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Sydney; FightMND
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS). Primary study aim: The clinical objective consists of assessing the efficacy of ALCAR (two different dosages will be tested: 1.5g/day and 3g/day) on the progression of functional disability (loss of self-sufficiency), as measured by the ALSFRS-R scale. Secondary study aims: 1. The effect of ALCAR treatment on different clinical aspects: functional decline as measured by ALSFRS-R total score; the decline of forced vital capacity (FVC); quality of life as measured by ALSAQ-40 scale; cognitive function as measured by Edinburgh Cognitive and Behavioural ALS Screen (ECAS) scale; survival (being alive and without tracheostomy). 2. To measure the effects of ALCAR treatment on disease biomarkers potentially involved in the drug's mechanisms of action. These include PGC-1 alpha, 3-nitrotyrosine (3-NT), acetyl cyclophilin A (acetyl-PPIA), neurofilament light chain (NFL), creatine kinase (CK), Musclin/osteocrin, MyomiRNA (MiR-206), Uric acid, Matrix metalloproteinase-9 (MMP-9), Monocyte Chemoattractant Protein-1 (MCP-1), 4-Hydroxynonenal (HNE). 3. The tolerability and safety of ALCAR treatment by identifying unexpected adverse events. Study population: 246 subjects will be enrolled on one Australian and ten Italian ALS sites. Inclusion criteria: subjects aged 18+ years with a diagnosis of ALS according to Gold Coast Criteria; disease duration \<24 months; satisfactory bulbar and spinal function (self-sufficiency evaluated by a score 3+ on the ALSFRS-R for swallowing, cutting food and handling utensils, and walking); satisfactory respiratory function (FVC ≥80% of predicted); documented progression of symptoms as measured by the ALSFRS-R scale. Disease progression rate (DFS) must be\>= 0.33. DFS =(48- ALSFRS-R at screening)/months from onset to screening, treatment with Riluzole in the last four weeks. Exclusion criteria: antecedent polio infection; other motor neuron disease; involvement of other systems possibly determining a functional impairment; other severe clinical conditions; unwillingness or inability to take riluzole; previous use of ALCAR for any reason; inability to understand and comply with the study requirements, and to give written informed consent personally or via their legally authorized representative. All eligible participants will be randomized to receive ALCAR (1,5 or 3 g/day) or placebo in addition to riluzole 50 mg b.i.d. Permuted block (with a block size of 6), 1:1:1 centralized randomization scheme will be used. The overall treatment duration will be 48 weeks. After enrolment, each participant will be followed up until death. Eligible subjects will be seen after 4, 12, 24, 36 and 48 weeks. At each visit, a general assessment will be made, including vital signs, body mass index (BMI), neurological examination (including quantitative and qualitative evaluation of the motor system), comorbidity, concomitant treatments and adverse events. Blood samples will be collected at baseline -Day 1 (randomization)-, 4, 12, 24, 36 and 48 weeks to test biomarkers. Functional disability will be assessed at each visit using the ALS-FRS-R scale. The respiratory function will be assessed using a spirometer to measure FVC before starting treatment (baseline visit) and at 4, 12, 24, 36 and 48 weeks. Cognitive function will be evaluated at baseline, weeks 24 and 48, using ECAS scale. Health-related quality of life, measured by the ALSAQ-40, will be tested at baseline, 24 and 48 weeks. Compliance will be tested by the local investigators, counting unused packages at each follow-up visit. Pre-planned statistical analyses will be done on Intention-to-treat and Per-protocol (PP) populations. The statistical plan will include descriptive statistics and a comparison of the proportions of self-sufficient participants at week 48 using the chi-square or Fisher's exact test for the primary endpoint. Secondary endpoints measured by numerical scores obtained from clinical scales will be analyzed using repeated measures mixed models, while biomarkers using repeated measures ANOVA. Time-to-event endpoints, such as survival and the probability of remaining self-sufficient over 48 weeks, will be analyzed with Kaplan-Meier curves. The number of adverse events and serious adverse events after 48 weeks will be compared between treatment arms.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
Acetyl-l-carnitineDrug
Acetyl-l-carnitine
PlaceboDrug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- self-sufficientTime frame: 48 weeks
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
Concord Hospital
Sydney, Australia, Australia · Recruiting
Fondazione Serena ONLUS Centro Clinico NEMO Brescia
Brescia, Brescia, Italy · Recruiting
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Dipartimento di Neurologia
Bergamo, Italy, Italy · Recruiting
Istituto Auxologico Italiano, IRCCS Dipartimento di Neurologia
Milan, Italy, Italy · Recruiting
Azienda Ospedaliera Universitaria Federico II Di Napoli
Naples, Italy, Italy · Recruiting
Azienda Ospedaliera Universitaria "Luigi Vanvitelli", Dipartimento di Scienze mediche e chirurgiche avanzate
Naples, Italy, Italy · Not yet recruiting
Azienda Ospedaliero-Universitaria Maggiore della Carità
Novara, Italy, Italy · Recruiting
Azienda Ospedale-Università di Padova, Unità di Neurologia Clinica
Padova, Italy, Italy · Recruiting
A.S.P. Palermo, Villa delle Ginestre Hospital
Palermo, Italy, Italy · Not yet recruiting
Fondazione Serena ONLUS-Centro Clinico NEMO Trento
Pergine Valsugana, Italy, Italy · Recruiting
Azienda Ospedaliera di Perugia
Perugia, Italy, Italy · Not yet recruiting
Azienda Ospedaliero Universitaria Pisana, Dipartimento di Medicina Clinica e Sperimentale
Pisa, Italy, Italy · Not yet recruiting
San Camillo Forlanini Hospital, Center for Neuromuscolar and Neurological Rare Diseases, Unit of Neurology and Neurophysiopathology
Roma, Italy, Italy · Not yet recruiting
Fondazione Serena ONLUS - Centro Clinico NeMO Ancona
Torrette, Italy, Italy · Recruiting
Fondazione Serena ONLUS centro clinico NEMO
Milan, Milano, Italy · Recruiting
AOU di Modena Nuovo Ospedale Civile S. Agostino Estense di Modena - Ospedale di Baggiovara
Modena, Modena, Italy · Recruiting
Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS
Pavia, Pavia, Italy · Recruiting
Azienda Ospedaliero Universitaria Pisana
Pisa, Pisa, Italy · Recruiting
Azienda Ospedaliero-Universitaria Policlinico Umberto I - Università di Roma "La Sapienza"
Roma, Roma, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.